Trial Profile
A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With RAS (KRAS, NRAS) Wild-type, Unresectable, Advanced/Recurrent Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms APOLLON
- Sponsors Takeda
- 19 Jan 2019 Results of final analysis, including follow-up presented at the 2019 Gastrointestinal Cancers Symposium.
- 05 Jun 2018 Primary endpoint has (Phase II part: Progression free survival rate at 6 months PFS.) not been met, according to the results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology